干细胞治疗神经系统疾病现状的思考：是希望还是炒作？

背景：干细胞研究已50年，干细胞体外分离、培养、纯化和鉴定技术已经相对成熟，干细胞替代治疗神经系统疾病已在临床开展，但在缺少统一应用规范的情况下不免出现一些负面报道和夸大宣传，面对这些很多医生、患者出现了迷惘。目的：探讨干细胞治疗神经系统疾病到底是希望？还是炒作？方法：通过①对人民日报近期发表的两篇影响较大的干细胞临床应用相关报道的思考。②结合作者自身多年开展干细胞治疗神经系统疾病的一些经验。③参考国内外一些研究文献等多条线索进行剖析。以“干细胞”、“动物模型”、“神经”等检索词变换组合检索万方数据库和Pubmed全文数据库1999年1月至2012年4月相关资料，获得文献阅读后进一步剔除。结果与结论：在动物实验方面，神经干细胞对于神经系统损伤及退行性变有一定治疗作用。在干细胞的临床应用研究方面，受到很多限制。面对阻力，一些国家已经从国家层面展开具有一定规模的临床试验，大多己进入临床Ⅱ、Ⅲ期。美国代表性产品Prochymal成为全球首个获准用于临床治疗人体疾病的干细胞药物。产业化的干细胞成品具有巨大的研究价值和应用前景。但在疗效不确切的情况下，暂不主张在临床上大规模推广应用，更不主张以盈利为目的、夸大其词的商业化宣传。

Alternative treatment with stem cells for treatment of nervous system diseases： Hope or hype？

BACKGROUND： Stem cells have been studied for over 50 years. The technology of isolating, culturing, purifying and identifying stem calls has been well mastered. The alternative treatment with stem cells for diseases of the nervous system has been used in the clinic. With being lack of uniform standard, there are some negative or hype reports, which trouble doctors and patients. OBJECTIVE： To investigate the alternative treatment with stem cells for treatment of nervous system diseases is hope or hype？ METHODS： Based on the insights on the reports on clinical application of stem calls Published recently in People＇s Daily and our clinical experiences in alterative treatment with stem cells for diseases of the nervous system, we analyzed the alternative treatment with stem cells for treatment of nervous system diseases after an online retrieval of Wanfang and PubMed databases （1999-01/2012-04） using the key words ＂stem cells, animal model, nerve＂ for papers regarding stem calls. RESULTS AND CONCLUSION： Animal experiments showed that neural stem calls exhibit some therapeutic effects on nervous system injury and degenerative diseases. Clinical application of stem calls is much restricted. Some countries have developed some large-scale clinical experiments and most of which are at clinical Ⅱ and Ⅲ phrases. Prochymal, a representative US product, has become the first global drug that has been approved to be used for treatment of systematic diseases. Industrialized stem call products hold a great promise in clinical application. However, these stem call products are not advocated to be widely used because of uncertain therapeutic effects and exaggerated commercial propaganda of stem cell products for financial gains are not desirable.